SCHEMBL2706490

SCHEMBL2706490

CC1(C2CCCCC2)CO1

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706488 1.00 MAPK1 (0.32) MAPK1NPSR1
SCHEMBL6470444 0.82
SCHEMBL1685367 0.76 KDM4E (0.31)
SCHEMBL3293871 0.74 KMT2A (0.31)
SCHEMBL13342645 0.72 L3MBTL1 (0.37) MAPK1
SCHEMBL9488890 0.71 CHRM2 (0.31)
SCHEMBL12849082 0.71 TRPA1 (0.40)
SCHEMBL14583496 0.70 KMT2A (0.39)
SCHEMBL10986631 0.69
SCHEMBL11089761 0.67 TERT (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116903654-A Hydrophobic modifier, preparation method thereof and method for preparing modified inorganic filler 南开大学 2023-10-20 CN claimed
CN-116903654-A Hydrophobic modifier, preparation method thereof and method for preparing modified inorganic filler 南开大学 2023-10-20 CN disclosed
WO-2021132234-A1 MULTILAYER BODY 住友化学株式会社 2021-07-01 WO disclosed
WO-2021132236-A1 OPTICAL LAMINATE 住友化学株式会社 2021-07-01 WO disclosed
US-20150315188-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION MEDIVATION TECHNOLOGIES, INC. 2015-11-05 US disclosed
EP-2887805-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION Medivation Technologies, Inc. (US) 2015-07-01 EP disclosed
WO-2014031167-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION MEDIVATION TECHNOLOGIES, INC. (US) 2014-02-27 WO disclosed
WO-2014031170-A1 PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2014-02-27 WO disclosed
WO-2014031165-A1 COMPOUNDS AND METHODS OF TREATING DIABETES MEDIVATION TECHNOLOGIES, INC. (US) 2014-02-27 WO disclosed
CN-101400664-B Method for crystallization of epoxy compound SUMITOMO CO LTD 2012-09-05 CN disclosed
US-8198069-B2 Method of producing an optically enriched tertiary alcohol from an epoxide using halohydrin dehalogenase BASF SE (DE) 2012-06-12 US disclosed
EP-1966385-B1 A process for the production of an optically enriched tertiary alcohol BASF SE (DE) 2012-05-02 EP disclosed
US-20080299626-A1 Process For the Production of an Optically Enriched Tertiary Alcohol BASF AKTIENGESELLSCHAFT (DE) 2008-12-04 US disclosed
EP-1966385-A2 A PROCESS FOR THE PRODUCTION OF AN OPTICALLY ENRICHED TERTIARY ALCOHOL BASF SE (DE) 2008-09-10 EP disclosed
WO-2007071599-A2 A PROCESS FOR THE PRODUCTION OF AN OPTICALLY ENRICHED TERTIARY ALCOHOL BASF SE (DE) 2007-06-28 WO disclosed
EP-0099375-B1 PROCESS FOR TREATING USED MOTOR OIL AND SYNTHETIC CRUDE OIL NORMAN, George R. (US) 1987-09-02 EP disclosed
US-4432865-A REACTING WITH MINERAL ACID OR POLYHYDROXY COMPOUND, THEN SEPARATION NORMAN GEORGE R 1984-02-21 US disclosed
US-4431524-A DEMETALLIZATION BY ADDING A MINERAL ACID AND POLYHYDROXY COMPOUND SUCH AS CELLULOSE FIBERS NORMAN GEORGE R 1984-02-14 US disclosed
US-4382128-A Polyolefin grafted with polycarboxylic acid, ester or anhydride and modified with polyhydroxy compound STANDARD OIL COMPANY (US) 1983-05-03 US disclosed
US-4144027-A SHRINKPROOFING KERATIN-CONTAINING FABRICS BY REACTION WITH A POLYETHER POLYOL AND A DIISOCYANATE MILLIKEN RESEARCH CORPORATION (US) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315188-A1 COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION ADRB2, ADRA2B, ADRB1 MAPK1 1470/4885NPSR1 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.